Hotgen(SH:688068) Xin Lang Cai Jing·2025-09-02 03:58Core Points - The stock price of Hotgen Biotech has dropped by 5.15% on September 2, reaching 194.10 CNY per share, with a trading volume of 420 million CNY and a turnover rate of 2.26%, resulting in a total market capitalization of 17.995 billion CNY. The stock has seen a continuous decline for five days, with a cumulative drop of 16.76% during this period [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, is primarily engaged in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: testing reagents 70.87%, testing instruments 19.79%, others 8.17%, and biological raw materials 1.17% [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Harvest Fund has a significant position in Hotgen Biotech. The Harvest CSI 2000 ETF (159535) held 409 shares in the second quarter, accounting for 0.28% of the fund's net value, ranking as the eighth largest holding. The estimated floating loss today is approximately 4,306.77 CNY, with a total floating loss of 16,900 CNY over the five-day decline [2] - The Harvest CSI 2000 ETF (159535) was established on September 14, 2023, with a latest scale of 20.5767 million CNY. Year-to-date, it has achieved a return of 34.49%, ranking 1161 out of 4222 in its category; over the past year, it has returned 75.74%, ranking 857 out of 3781; and since inception, it has returned 40.56% [2] Fund Manager Information - The fund manager of the Harvest CSI 2000 ETF (159535) is Li Zhi, who has been in the position for 7 years and 253 days. The total asset size of the fund is 18.361 billion CNY, with the best fund return during his tenure being 82.77% and the worst being -50.62% [3]